Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 8/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276431 | 0.89 | ARF6 (0.45) | ARF6TNKSMARS1ALDH1A1MAPT | |
| SCHEMBL10275442 | 0.85 | ARF6 (0.41) | ARF6TNKSMARS1MAPTSMN1; SMN2 | |
| SCHEMBL10275459 | 0.85 | ARF6 (0.43) | ARF6MARS1ALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL10275925 | 0.84 | PLAT (0.40) | ARF6ALDH1A1MAPTSMN1; SMN2TDP1 | |
| SCHEMBL10275250 | 0.83 | ARF6 (0.42) | ARF6TNKSMARS1DPP4CNR1 | |
| SCHEMBL10275490 | 0.83 | ARF6 (0.41) | ARF6MARS1DPP4CNR1CNR2 | |
| SCHEMBL10276429 | 0.80 | ARF6 (0.43) | ARF6ALDH1A1DPP4CNR1CNR2 | |
| SCHEMBL1278782 | 0.77 | ARF6 (0.58) | ARF6PSD | |
| SCHEMBL27949830 | 0.77 | ARF6 (0.48) | ARF6MARS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10313835 | 0.76 | ARF6 (0.56) | ARF6ALDH1A1DPP4PSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | ARF6 3355/4885TNKS 2005/4885MARS1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.